Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$10.36−0.51 (-4.69%)

Close on Nov 13, 2026Market cap $595.04MP/E –Yield –

Climb Bio gross margin

Gross margin is gross profit as a percentage of revenue.

Climb Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?